Turnes Juan, García-Pagán Juan Carlos, González Monica, Aracil Carles, Calleja José Luís, Ripoll Cristina, Abraldes Juan G, Bañares Rafael, Villanueva Cándido, Albillos Agustín, Ayuso Juan Ramón, Gilabert Rosa, Bosch Jaime
Hepatic Hemodynamic Laboratory,Institut Malalties Digestives i Metabòliques, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Clin Gastroenterol Hepatol. 2008 Dec;6(12):1412-7. doi: 10.1016/j.cgh.2008.07.031.
BACKGROUND & AIMS: Acute portal vein thrombosis (APVT) is a rare disorder that causes chronic portal hypertension if recanalization is not obtained. However, response to anticoagulation and long-term prognosis of APVT are not well-defined.
Thirty-eight patients diagnosed with APVT between 1995 and 2003 from 5 Spanish referral hospitals, in whom cirrhosis and malignancy were specifically excluded, were included in this retrospective study. The response to anticoagulation therapy and development of portal hypertension-related complications during follow-up were evaluated.
Mean follow-up was 43 months (range, 6-112 months). Recanalization occurred in 12 of 27 patients receiving anticoagulation versus 0 of 11 patients who did not receive anticoagulation (P = .008). Rates of recanalization were influenced by the precocity of heparin administration and the number of underlying prothrombotic conditions. Follow-up upper endoscopy performed in 29 patients disclosed gastroesophageal varices in 16 (55%). Varices appeared as early as 1 month after APVT. However, in most patients varices were detected in successive endoscopies, mainly during the first year. Two-year actuarial probability of variceal bleeding was 12% and for ascites 16%. Five-year survival was 87%. Mortality was related to the APVT episode in 2 cases and to an underlying hematologic disorder in one.
Anticoagulation achieved recanalization in about 40% of patients. Most patients not achieving recanalization will develop gastroesophageal varices during follow-up. However, development of variceal bleeding and ascites is infrequent, and survival is satisfactory.
急性门静脉血栓形成(APVT)是一种罕见疾病,若不能实现再通则会导致慢性门静脉高压。然而,APVT对抗凝治疗的反应以及长期预后尚不明确。
本回顾性研究纳入了1995年至2003年间来自5家西班牙转诊医院的38例诊断为APVT的患者,这些患者被特意排除了肝硬化和恶性肿瘤。评估了抗凝治疗的反应以及随访期间门静脉高压相关并发症的发生情况。
平均随访时间为43个月(范围6 - 112个月)。27例接受抗凝治疗的患者中有12例实现了再通,而11例未接受抗凝治疗的患者中无一例再通(P = 0.008)。再通率受肝素给药的及时性以及潜在血栓形成前状态的数量影响。29例患者接受的随访上消化道内镜检查显示,16例(55%)有食管胃静脉曲张。静脉曲张最早在APVT后1个月出现。然而,在大多数患者中,静脉曲张是在连续的内镜检查中发现的,主要是在第一年。静脉曲张出血的两年精算概率为12%,腹水为16%。五年生存率为87%。死亡与APVT发作相关的有2例,与潜在血液系统疾病相关的有1例。
抗凝治疗使约40%的患者实现了再通。大多数未实现再通的患者在随访期间会出现食管胃静脉曲张。然而,静脉曲张出血和腹水的发生并不常见,且生存率令人满意。